Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine ki...

Full description

Bibliographic Details
Main Authors: Huamiao Zhou, Binyue Xu, Jili Xu, Guomeng Zhu, Yong Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
NSCLC
MRPS9-ALK
NGS
crizotinib
ALK-TKI
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.670907/full

Similar Items

Similar Items